Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Shares Outstanding (Diluted Average) (2023 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 215.53% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 215.53% year-over-year, with the annual reading at $1.6 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $4.5 million at Neuphoria Therapeutics, up from $2.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $981.6 million in Q2 2023, with the low at $1.3 million in Q3 2024.
  • Average Shares Outstanding (Diluted Average) over 3 years is $142.0 million, with a median of $1.6 million recorded in 2025.
  • Peak annual rise in Shares Outstanding (Diluted Average) hit 215.53% in 2025, while the deepest fall reached 72.77% in 2025.
  • Over 3 years, Shares Outstanding (Diluted Average) stood at $981.6 million in 2023, then tumbled by 99.85% to $1.4 million in 2024, then skyrocketed by 215.53% to $4.5 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $4.5 million, $2.2 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.